Core Viewpoint - Teva Pharmaceuticals and Medincell announced that the FDA has accepted the New Drug Application for TEV-'749, an extended-release injectable suspension of olanzapine aimed at improving treatment adherence for schizophrenia patients [1][2][3] Company Overview - Teva Pharmaceutical Industries Ltd. is transitioning into a leading innovative biopharmaceutical company, supported by a strong generics business, with a focus on neuroscience and immunology [8] - Medincell is a biopharmaceutical company developing long-acting injectable drugs, utilizing proprietary technology to enhance medication compliance and effectiveness [10] Product Details - TEV-'749 is a once-monthly subcutaneous injection of olanzapine, designed to address the lack of long-acting formulations without the need for post-injection monitoring [2][6] - The product utilizes SteadyTeq™, a proprietary copolymer technology from Medincell, which allows for controlled and sustained release of olanzapine [4] Clinical Trial Insights - The NDA for TEV-'749 is based on the Phase 3 SOLARIS trial, which demonstrated an efficacy and safety profile consistent with existing olanzapine formulations [3][5] - The SOLARIS trial involved 675 patients aged 18 to 64, randomized to receive TEV-'749 or placebo, with a primary objective to evaluate efficacy in treating schizophrenia [5] Market Need - There is a significant unmet need for long-acting olanzapine formulations, as treatment adherence remains a major challenge for schizophrenia patients [3][6] - Approximately 1% of the global population will develop schizophrenia, with 3.5 million diagnosed in the U.S., highlighting the potential market for TEV-'749 if approved [7]

Core Viewpoint - Teva Pharmaceuticals reported Q4 and full-year 2025 results for UZEDY®, indicating strong sales performance and providing a positive outlook for 2026 [1] Group 1: Financial Performance - UZEDY® net sales for 2025 reached $191 million, with $55 million generated in the fourth quarter [1] - Teva's initial net sales outlook for UZEDY® in 2026 is projected to be between $250 million and $280 million [1] Group 2: Royalty Information - Medincell receives mid to high single-digit royalties on UZEDY® net sales [1] - Medincell is eligible for up to $105 million in royalties [1]